Devices/Warning Letter·FDA Warning Letters

Warning Letter — AseptiKits, LLC

MediumPublished Jun 30, 2026· AI-analyzed Jun 30, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

The FDA issued a Warning Letter to AseptiKits, LLC on June 4, 2026, following an evaluation by the Center for Devices and Radiological Health (CDRH).

Who it affects

This notice affects AseptiKits, LLC, as well as regulatory and quality personnel involved in the manufacturing and distribution of medical device kits.

Why it matters

The issuance of a Warning Letter by CDRH signifies that prior responses to inspectional observations may have been deemed inadequate by the agency. This represents an escalation in enforcement that could lead to restricted product distribution or the withholding of future device approvals until the documented violations are remediated.

Practical takeaway

Review internal Quality Management System (QMS) protocols to ensure alignment with CDRH expectations. Conduct an immediate audit of any outstanding FDA inspection observations to ensure CAPA plans are sufficient to prevent escalation to a Warning Letter.

FDA source material

FDA Warning Letter issued to: AseptiKits, LLC. 06/04/2026 — Center for Devices and Radiological Health. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aseptikits-llc-728184-06042026

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.